Our ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of our innovative peptide technology.
Our focus is on applying our peptide technology across a wide range of indications through independent and partnered development pathways.
We’re looking for passionate, innovative individuals who can help us to deliver our technology to the people who need it most, and we’ve fostered a unique working culture to support this mission.
We are excited to announce that PepGen will be part of an international project focusing on the role of the brain in Duchenne and Becker muscular dystrophy. Further details on this project can be found in the press release below: The BIND project is the first…
A recent publication utilising the precursor technology that underpins PepGen’s platform has been awarded ‘Paper of the Month‘ by the Board of Directors and the Scientific Advisory Council of the Oligonucleotide Therapeutics Society (OTS). In addition, this publication is currently under consideration for the…
PepGen attended the BioTrinity conference from the 29th of April to the 1st of May 2019. The company was represented by Damian Marron (Chairman of the Board), Dr Caroline Godfrey (CEO) and Dr Sonia Bracegirdle (CBO) at this event. Alongside meetings with potential investors and partners,…
